FDA Again Rejects Allergan Migraine Drug Levadex
Allergan Inc. announced Tuesday that the U.S. Food and Drug Administration has again declined to grant regulatory approval for its pending migraine treatment Levadex, citing issues with the manufacture of the...To view the full article, register now.
Already a subscriber? Click here to view full article